Position in NVS
as of Jun 30, 2026
· filed Jul 21, 2026
Position Value
$1,307,983
+$38,173 QoQ
Shares Held
8,346
+0.4% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.91%
of 13F equity value
Holder Rank
#549
of 1,603 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026YANKCOM Partnership holds $10,492,639 across 10 Drug Manufacturers - General names. NVS ranks #5 (12.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
10,163 | $2,557,415 | |
| 2 | LLY |
ELI LILLY & Co
|
2,031 | $2,436,042 | |
| 3 | MRK |
Merck & Co., Inc.
|
16,362 | $2,102,516 | |
| 4 | JNJ |
Johnson & Johnson
|
6,002 | $1,524,326 | |
| 5 | NVS |
Novartis AG
This page
|
8,346 | $1,307,983 | |
| 6 | AMGN |
Amgen Inc
|
1,341 | $485,602 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
270 | $34,110 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
322 | $18,553 |
All Filings in NVS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,307,983 | 8,346 | Shares | Sole | 2026-07-21 | |
| 2026-03-31 | $1,269,810 | 8,313 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $1,171,756 | 8,499 | Shares | Sole | 2026-01-20 | |
| 2025-09-30 | $1,078,369 | 8,409 | Shares | Sole | 2025-10-20 | |
| 2025-06-30 | $1,089,573 | 9,004 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $998,859 | 8,960 | Shares | Sole | 2025-04-29 | |
| 2024-12-31 | $803,876 | 8,261 | Shares | Sole | 2025-01-27 | |
| No filing history on record for this holder in this stock. | ||||||